Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

WALTERS WILLIAM THURMAN — Zentalis Pharmaceuticals, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / WALTERS WILLIAM THURMAN

WALTERS WILLIAM THURMAN

10% owner at Zentalis Pharmaceuticals, Inc. · on record since Jan 8, 2026

Insider trading activity of WALTERS WILLIAM THURMAN

Transactions on record: 1; since Jan 8, 2026

Open-market buys: 1; $7.8M

Open-market sells: 0

Companies traded: 1; last filing Jan 8, 2026

Figures computed from official regulatory filings — methodology.

Companies where WALTERS WILLIAM THURMAN has traded

Zentalis Pharmaceuticals, Inc.1 tx · $7.8M · Jan 8, 2026

Track record of WALTERS WILLIAM THURMAN

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of WALTERS WILLIAM THURMAN

Co-insiders of WALTERS WILLIAM THURMAN

Blackwell KimberlyZentalis Pharmaceuticals, Inc.
Brownstein CarrieZentalis Pharmaceuticals, Inc.
Bruns IngmarZentalis Pharmaceuticals, Inc.
Bucher James BZentalis Pharmaceuticals, Inc.
Bunker Kevin D.Zentalis Pharmaceuticals, Inc.
Campbell ShannonZentalis Pharmaceuticals, Inc.
EASTLAND JULIA MARIEZentalis Pharmaceuticals, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Epperly Melissa B,Zentalis Pharmaceuticals, Inc.

Gallagher CamZentalis Pharmaceuticals, Inc.

GOEL DAVID E.Zentalis Pharmaceuticals, Inc.

HALVORSEN OLE ANDREASZentalis Pharmaceuticals, Inc.

HAUSMAN DIANAZentalis Pharmaceuticals, Inc.

Johnson David MichaelZentalis Pharmaceuticals, Inc.

Kariuki EnochZentalis Pharmaceuticals, Inc.

Lackner MarkZentalis Pharmaceuticals, Inc.

Matrix Capital Management Company, LPZentalis Pharmaceuticals, Inc.

Myers Scott DunsethZentalis Pharmaceuticals, Inc.

Ott David C.Zentalis Pharmaceuticals, Inc.

Paul AndreaZentalis Pharmaceuticals, Inc.

Pinto AlexisZentalis Pharmaceuticals, Inc.

Recurium Equity, LLCZentalis Pharmaceuticals, Inc.

Roth IrisZentalis Pharmaceuticals, Inc.

Shabet Rose SharonZentalis Pharmaceuticals, Inc.

Skvarka JanZentalis Pharmaceuticals, Inc.

SUN ANTHONY YZentalis Pharmaceuticals, Inc.

Takhar Karan S.Zentalis Pharmaceuticals, Inc.

VIKING GLOBAL INVESTORS LPZentalis Pharmaceuticals, Inc.

Viking Global Opportunities GP LLCZentalis Pharmaceuticals, Inc.

Viking Global Opportunities Illiquid Investments Sub-Master LPZentalis Pharmaceuticals, Inc.

Viking Global Opportunities Portfolio GP LLCZentalis Pharmaceuticals, Inc.

Voliotis DimitrisZentalis Pharmaceuticals, Inc.

Vultaggio VincentZentalis Pharmaceuticals, Inc.

Walker Luke NathanielZentalis Pharmaceuticals, Inc.

WALTERS GROUPZentalis Pharmaceuticals, Inc.

WALTERS SUSAN BERKLEYZentalis Pharmaceuticals, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Zentalis Pharmaceuticals, Inc.	Jan 8, 2026	Buy	6,459,973	1.20 USD	$7.8M	SEC